Online dosimetry for temoporfin-mediated interstitial photodynamic therapy using the canine prostate as model

Abstract. Online light dosimetry with real-time feedback was applied for temoporfin-mediated interstitial photodynamic therapy (PDT) of dog prostate. The aim was to investigate the performance of online dosimetry by studying the correlation between light dose plans and the tissue response, i.e., extent of induced tissue necrosis and damage to surrounding organs at risk. Light-dose planning software provided dose plans, including light source positions and light doses, based on ultrasound images. A laser instrument provided therapeutic light and dosimetric measurements. The procedure was designed to closely emulate the procedure for whole-prostate PDT in humans with prostate cancer. Nine healthy dogs were subjected to the procedure according to a light-dose escalation plan. About 0.15  mg/kg temoporfin was administered 72 h before the procedure. The results of the procedure were assessed by magnetic resonance imaging, and gross pathology and histopathology of excised tissue. Light dose planning and online dosimetry clearly resulted in more focused effect and less damage to surrounding tissue than interstitial PDT without dosimetry. A light energy dose–response relationship was established where the threshold dose to induce prostate gland necrosis was estimated from 20 to 30  J/cm2.

[1]  Stefan Andersson-Engels,et al.  System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer. , 2010, Journal of biomedical optics.

[2]  Stefan Andersson-Engels,et al.  Interstitial photodynamic therapy for primary prostate cancer incorporating real-time treatment dosimetry , 2007, SPIE BiOS.

[3]  K. Svanberg,et al.  In vivo optical characterization of human prostate tissue using near-infrared time-resolved spectroscopy. , 2007, Journal of biomedical optics.

[4]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[5]  Mark Emberton,et al.  Photodynamic therapy for prostate cancer—a review of current status and future promise , 2009, Nature Clinical Practice Urology.

[6]  C. Koch,et al.  Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. , 2002, Cancer research.

[7]  Hashim U. Ahmed,et al.  Photodynamic therapy for focal ablation of the prostate , 2010, World Journal of Urology.

[8]  S. C. Chang,et al.  Biological responses of dog prostate and adjacent structures after meso-tetra-(m-hydroxyphenyl) chlorin and aluminum disulfonated phthalocyanine based photodynamic therapy. , 1999, Proceedings of the National Science Council, Republic of China. Part B, Life sciences.

[9]  Timothy C Zhu,et al.  Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. , 2006, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[10]  Timothy C Zhu,et al.  Determination of in vivo light fluence distribution in a heterogeneous prostate during photodynamic therapy , 2008, Physics in Medicine and Biology.

[11]  D. Dearnaley,et al.  A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival , 2006, British Journal of Cancer.

[12]  M. Altschuler,et al.  Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm. , 2005, Medical physics.

[13]  Stefan Andersson-Engels,et al.  System for integrated interstitial photodynamic therapy and dosimetric monitoring , 2005, SPIE BiOS.

[14]  L. Lilge,et al.  Implicit and explicit dosimetry in photodynamic therapy: a New paradigm , 1997, Lasers in Medical Science.

[15]  Keith A. Cengel,et al.  Motexafin Lutetium-Photodynamic Therapy of Prostate Cancer: Short- and Long-Term Effects on Prostate-Specific Antigen , 2008, Clinical Cancer Research.

[16]  T J Dougherty,et al.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. , 1976, Cancer research.

[17]  Tayyaba Hasan,et al.  Pretreatment photosensitizer dosimetry reduces variation in tumor response. , 2006, International journal of radiation oncology, biology, physics.

[18]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[19]  Brian C. Wilson,et al.  Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. , 2005 .

[20]  M. Roos,et al.  Optimizing Photodynamic Therapy: In vivo Pharmacokinetics of Liposomal meta-(Tetrahydroxyphenyl)Chlorin in Feline Squamous Cell Carcinoma , 2005, Clinical Cancer Research.

[21]  C. Mosse,et al.  Ultrasound‐guided photodynamic therapy for deep seated pathologies: prospective study , 2009, Lasers in surgery and medicine.

[22]  Shi-Chung Chang,et al.  Interstitial and transurethral photodynamic therapy of the canine prostate using meso‐tetra‐(m‐hydroxyphenyl) chlorin , 1996, International journal of cancer.

[23]  Stefan Andersson-Engels,et al.  Feasibility study of a system for combined light dosimetry and interstitial photodynamic treatment of massive tumors. , 2002, Applied optics.

[24]  Stefan Andersson-Engels,et al.  Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements. , 2005, Applied optics.

[25]  A. Evans,et al.  Vascular‐targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses , 2008, BJU international.

[26]  P. Speight,et al.  Photodynamic therapy using mTHPC for malignant disease in the oral cavity , 1997, International journal of cancer.

[27]  M Emberton,et al.  Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer , 2006, Lasers in surgery and medicine.

[28]  Johannes Swartling,et al.  Realtime light dosimetry software tools for interstitial photodynamic therapy of the human prostate. , 2007, Medical physics.

[29]  Stephen G Bown,et al.  Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. , 2002, The Journal of urology.